Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis
Status:
Completed
Trial end date:
2013-08-28
Target enrollment:
Participant gender:
Summary
Pancreatitis is one of the major complications of ERCP. It has been shown that NSAIDs are
potent inhibitors of phospholipase A2, activity which is increased in pancreatitis. The only
one study with IM diclofenac showed reduction of post-ERCP pancreatitis without SOD
(sphincter of Oddi dysfunction) by subgroup analysis in small study population. Therefore the
investigators must need large scaled randomized control study including of SOD.